- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05566535
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice (QoL-PV-R)
September 30, 2022 updated by: Multinational Center for Quality of Life Research, Russia
Changes in Quality of Life (QoL) and Symptoms in Patients With Polycythemia Vera (PV) Receiving Ruxolitinib (Ruxo) in a Routine Clinical Practice
The purpose of this multicenter observational prospective cohort study is to examine changes in QoL and symptoms in patients with polycythemia vera (PV) during treatment with ruxolitinib (Ruxo), and to evaluate efficacy and safety of Ruxo in a real-world setting
Study Overview
Study Type
Observational
Enrollment (Anticipated)
32
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tatiana Nikitina, MD, PhD
- Phone Number: 89627101712
- Email: tnikitina_74@mail.ru
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients with PV will be enrolled after being prescribed with Ruxo.
The eligibility criteria for this study are broader than those for patients to be treated with Ruxo in randomized clinical trials, so as to be reflective of routine clinical practice
Description
Inclusion Criteria:
- Patients who have confirmed diagnosis of PV
- Patients whose age - 18 years and older
- Patients who signed informed consent
- Patients who able to fill out questionnaires
Exclusion Criteria:
- Patients enrolled in clinical trials
- Patients with contraindications to Ruxo in accordance with instruction for use
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in QoL as per SF-36 questionnaire domains at 3 and 9 months of Ruxo treatment
Time Frame: Baseline, 3 and 9 months of Ruxo treatment
|
The difference in QoL means of SF-36 domains at 3 and 9 months as compared to their Baseline will be analyzed
|
Baseline, 3 and 9 months of Ruxo treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in MPN10 Total score over time
Time Frame: Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The difference in MPN10 Total Symptom Score means by MPN10 at different time-points of Ruxo treatment as compared to their Baseline will be analyzed.
Also the percentage of patients with the lowest symptom burden, corresponding to MPN10 Total scores of 0 - 7 (quartile 1), at different treatment time-points (Baseline, 1, 3, 6, 9 and 12 months) will be calculated
|
Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
Change From Baseline in severity of each symptom by MPN10 over time
Time Frame: Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The difference in MPN10 symptom score means at different time-points of Ruxo treatment as compared to their Baseline will be analyzed
|
Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
Percentage of patients achieving a ≥ 50% improvement from Baseline in MPN10 Total Symptom Score over time
Time Frame: 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The number of patients with MPN10 Total Symptom Score decrease ≥ 50% at 1, 3, 6, 9 and 12 months of Ruxo treatment as compared to its' Baseline will be calculated
|
1, 3, 6, 9 and 12 months of Ruxo treatment
|
Change From Baseline in QoL as per SF-36 questionnaire domains over 12 months of Ruxo treatment
Time Frame: Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The difference in QoL means of SF-36 domains at different time-points of Ruxo treatment as compared to their Baseline will be analyzed
|
Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The percentage of patients who achieved overall clinicohematologic response at 9 months of treatment with Ruxo
Time Frame: 9 months
|
Overall clinicohematologic response will be defined as any participant who achieved a complete or partial clinicohematologic response per the National criteria for response in polycythemia vera (2021) and European LeukNet recommendations (2013).
A complete response (CR) will be defined as: hematocrit control (<45%) with the absence of phlebotomy eligibility ≥12 weeks, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 109/L, and white blood cell count less than or equal to 10 x 109/L, and symptom regress during ≥12 weeks as well as histological remission.
A Partial Response (PR) will be defined as all the above criteria excluding histological remission
|
9 months
|
The Percentage of patients who achieved hematocrit (Hct) control at 9 months of treatment with Ruxo
Time Frame: 9 months
|
Hematocrit control is Ht <45% with the absence of phlebotomy eligibility beginning at 3 months visit and continuing through 9 months
|
9 months
|
The percentage of patients with positive changes of wellbeing during Ruxo treatment
Time Frame: 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The number of patients who reported improvement as per Patient Global Impression of Changes scale at different time-points of treatment will be analyzed
|
1, 3, 6, 9 and 12 months of Ruxo treatment
|
The percentage of patients satisfied/dissatisfied with Ruxo treatment over time
Time Frame: 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The number of patients satisfied/dissatisfied with treatment according to Patient' Treatment Satisfaction Checklist at different time-points of treatment will be analyzed
|
1, 3, 6, 9 and 12 months of Ruxo treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2022
Primary Completion (Anticipated)
May 1, 2024
Study Completion (Anticipated)
August 1, 2024
Study Registration Dates
First Submitted
September 30, 2022
First Submitted That Met QC Criteria
September 30, 2022
First Posted (Actual)
October 4, 2022
Study Record Updates
Last Update Posted (Actual)
October 4, 2022
Last Update Submitted That Met QC Criteria
September 30, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CINC424BRU04T
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycythemia Vera
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan
-
Novartis PharmaceuticalsCompletedPolycythemia Vera (PV)United States
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
PharmaEssentia Japan K.K.Recruiting
-
PharmaEssentia Japan K.K.CompletedPolycythemia Vera (PV)Japan
-
Northwestern UniversityNational Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma SocietyWithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis PhaseUnited States
-
Ionis Pharmaceuticals, Inc.RecruitingPhlebotomy Dependent Polycythemia VeraUnited States, Canada, Hungary, United Kingdom, Australia, Poland
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Clinical Trials on Ruxolitinib
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Incyte CorporationCompleted
-
University of ZurichIncyte CorporationNot yet recruitingExanthema | Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingSevere Aplastic Anemia | Single Lineage Cytopenias, T-LGL | Hypoplastic MDSUnited States
-
Qilu Hospital of Shandong UniversityRecruiting
-
Memorial Sloan Kettering Cancer CenterDana-Farber Cancer Institute; Thomas Jefferson University; Cornell UniversityRecruiting
-
Children's Hospital Medical Center, CincinnatiCompletedSolid Organ Transplant | Acute-graft-versus-host Disease | Chronic Graft-versus-host-diseaseUnited States